Eli Lilly Dives As Zepbound Takes A Back Seat To Novo Nordisk's Wegovy At CVSInvestors Business Daily • 05/01/25
Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer treatment dealCNBC • 05/01/25
Lilly reports first-quarter 2025 financial results and highlights pipeline momentumPRNewsWire • 05/01/25
Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loomCNBC • 04/30/25
Eli Lilly's Stock Is Up 15% This Year, and Here's Why It Could Take Off Even MoreThe Motley Fool • 04/30/25
Creyon Bio and Lilly Enter into RNA-Targeted Oligo Therapy Development CollaborationBusiness Wire • 04/29/25
Is Eli Lilly Stock a Portfolio Must-Have Pre-Q1 Earnings? (Revised)Zacks Investment Research • 04/28/25
Ahead of Lilly (LLY) Q1 Earnings: Get Ready With Wall Street Estimates for Key MetricsZacks Investment Research • 04/28/25
Eli Lilly: Positioned For Robust Q1 As Orforglipron Enhances Long-Term OutlookSeeking Alpha • 04/25/25
Exclusive: US pharma tariffs would raise US drug costs by $51 bln annually, report findsReuters • 04/25/25